HC Wainwright Research Analysts Increase Earnings Estimates for ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA)

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) – Equities researchers at HC Wainwright upped their Q2 2024 earnings per share estimates for ZyVersa Therapeutics in a report released on Tuesday, March 26th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($0.52) per share for the quarter, up from their previous estimate of ($0.53). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for ZyVersa Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for ZyVersa Therapeutics’ FY2025 earnings at ($4.61) EPS, FY2026 earnings at ($6.58) EPS, FY2027 earnings at ($8.89) EPS and FY2028 earnings at ($11.17) EPS.

ZyVersa Therapeutics Stock Up 3.8 %

ZVSA stock opened at $0.78 on Thursday. The company has a 50-day simple moving average of $0.73 and a 200 day simple moving average of $2.10. ZyVersa Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $90.65.

Institutional Trading of ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Walleye Capital LLC bought a new position in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned approximately 3.17% of ZyVersa Therapeutics at the end of the most recent reporting period. 3.91% of the stock is currently owned by institutional investors.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.